The federal government affirmed its plan to limit coverage for a costly new medication for Alzheimer’s disease, restricting it to Medicare patients enrolled in clinical trials.
Those trials could be approved by the FDA itself or by the National Institutes of Health, and would not have to be sanctionedIn a small victory for Alzheimer’s patients, CMS said if the FDA approves future drugs through a more traditional process, it would allow wider access to coverage for those medications. Those drugs also would target the amyloid plaques suspected of causing the devastating impacts of Alzheimer’s.
But some major health systems have refused to offer the medication, developed by the drugmaker Biogen, because some experts doubt its efficacy. The watchdog group Public Citizen — which frequently criticizes the FDA — called for
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
New generation of cancer-preventing vaccines could wipe out tumors before they formCancer-preventing vaccines are now being tested in healthy people at high risk for disease—and early trials are yielding glimmers of promise. LongReads
Weiterlesen »
San Diego will be part of national clinical trial on COVID-19 vaccinesEffort will be led locally by UC San Diego with almost half of participants 65 or older
Weiterlesen »
UCSD joins clinical trial to evaluate need for additional COVID-19 boostersUC San Diego joined a Phase II clinical trial to evaluate additional COVID-19 booster shots to see if different vaccine regimens can broaden immune responses in adults, it was announced Wednesday.
Weiterlesen »
UCSD joins clinical trial to evaluate need for additional COVID-19 boostersUC San Diego joined a Phase II clinical trial to evaluate additional COVID-19 booster shots to see if different vaccine regimens can broaden immune responses in adults, it was announced Wednesday.
Weiterlesen »
Pfizer to Buy Respiratory-Virus DrugmakerThe New York drugmaker said it agreed to acquire the clinical-stage biopharmaceutical company that is targeting respiratory syncytial virus, which can lead to severe lower-respiratory-tract infections.
Weiterlesen »